dc.contributor.author | Schmidinger, M | |
dc.contributor.author | Porta, C | |
dc.contributor.author | Oudard, S | |
dc.contributor.author | Denechere, G | |
dc.contributor.author | Brault, Y | |
dc.contributor.author | Serfass, L | |
dc.contributor.author | Costa, N | |
dc.contributor.author | Larkin, J | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2022-08-30T09:35:15Z | |
dc.date.available | 2022-08-30T09:35:15Z | |
dc.date.issued | 2020-10-01 | |
dc.identifier | S1558-7673(20)30047-1 | |
dc.identifier.citation | Clinical Genitourinary Cancer, 2020, 18 (5), pp. e588 - e597 | en_US |
dc.identifier.issn | 1558-7673 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5340 | |
dc.identifier.eissn | 1938-0682 | |
dc.identifier.eissn | 1938-0682 | |
dc.identifier.eissn | 1938-0682 | |
dc.identifier.eissn | 1938-0682 | |
dc.identifier.doi | 10.1016/j.clgc.2020.02.013 | |
dc.description.abstract | BACKGROUND: ADONIS is an ongoing observational study in 9 European countries, designed to evaluate treatment patterns/outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line sunitinib and/or second-line axitinib post sunitinib. We present an evaluation of sunitinib efficacy by risk group, in the real-world setting examined in ADONIS. PATIENTS AND METHODS: Patients were enrolled at the start of first-line sunitinib treatment or second-line axitinib post sunitinib treatment. Evaluation of sunitinib efficacy was assessed by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and Memorial Sloan Kettering Cancer Center risk criteria. RESULTS: For all patients in this analysis (N = 467), the median progression-free survival was 23.8 months (95% confidence interval [CI], 16.5-28.5 months), 11.8 months (95% CI, 8.1-17.4 months), and 4.6 months (95% CI, 2.5-7.7 months) for IMDC favorable-, intermediate-, and poor-risk groups, respectively. The median overall survival was 97.1 months (95% CI, 46.3 months-not evaluable [NE]), 33.5 months (95% CI, 20.5-46.6 months), and 10.0 months (95% CI, 4.5-19.8 months) for the respective risk groups. Data on individual risk factors were available for a subgroup of patients, allowing analysis by intermediate risk by 1 versus 2 risk factors. When including this subgroup (n = 120), the median overall survival for IMDC favorable-, intermediate-1, and intermediate-2 risk factors was 21.6 months (95% CI, 16.3 months-NE), 20.5 months (15.5 months-NE), and 15.1 months (4.1 months-NE), respectively. CONCLUSIONS: For patients overall and by risk-group stratification, survival estimates were aligned with previously published data. In patients with intermediate-1 risk, overall survival was very similar to patients with favorable risk. However, further exploration of outcome data from different sources is needed to confirm these observations. | |
dc.format | Print-Electronic | |
dc.format.extent | e588 - e597 | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | CIG MEDIA GROUP, LP | en_US |
dc.relation.ispartof | Clinical Genitourinary Cancer | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.subject | ADONIS trial | |
dc.subject | Intermediate-risk | |
dc.subject | Kidney cancer | |
dc.subject | Risk stratification | |
dc.subject | Targeted therapy | |
dc.subject | Antineoplastic Agents | |
dc.subject | Carcinoma, Renal Cell | |
dc.subject | Disease-Free Survival | |
dc.subject | Humans | |
dc.subject | Kidney Neoplasms | |
dc.subject | Retrospective Studies | |
dc.subject | Risk Factors | |
dc.subject | Sunitinib | |
dc.subject | Treatment Outcome | |
dc.title | Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-02-25 | |
dc.date.updated | 2022-08-30T09:33:00Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1016/j.clgc.2020.02.013 | en_US |
rioxxterms.licenseref.startdate | 2020-10-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/32586677 | |
pubs.issue | 5 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.publication-status | Published | |
pubs.volume | 18 | |
dc.contributor.icrauthor | Larkin, James | |
icr.provenance | Deposited by Mr Arek Surman on 2022-08-30. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S1558767320300471-main.pdf | |